New stimulant EB-1020 put to the test: will it be abused?

NCT ID NCT02144415

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a new drug called EB-1020 has abuse potential in 80 healthy adults who use stimulants recreationally. Participants received single doses of EB-1020, d-amphetamine, or placebo, and rated how much they liked the drug. The goal was to see if EB-1020 produces a 'high' similar to other stimulants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EB-1020 immediate-release capsules

What this could lead to

If EB-1020 shows low abuse potential, it may be developed as a safer stimulant alternative for conditions like ADHD.

What could go wrong

This is an early Phase 1 study in healthy volunteers, not patients. The results may not predict real-world abuse or effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type Drug Misuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vince and Associates Clinical Research, Inc.

    Overland Park, Kansas, 66212, United States